CLINICAL_TRIALS
trial_result
· 2011-07-20
Clinical Trial Update: Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia [Phase 2]
Summary
A Phase 2 trial evaluating sargramostim after allogeneic bone marrow transplantation in patients with chronic myeloid leukemia was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Leukemia | Phase 2 | Status: TERMINATED